Imaging Biomarkers for Oligometastatic Colorectal Cancer
There is a widening therapeutic opportunity for treating ‘oligometastatic’ cancer with radical intent. However, both oligometastatic cancer and, importantly, the patients who benefit from intervention remain poorly defined. The tumour biology is heterogeneous and patient outcomes are variable, suggesting improved biomarkers are needed to select treatment strategies appropriately.
Multimodal imaging already has a central role in defining the disease burden in patients with limited metastatic cancer. However, modern imaging techniques can also provide additional phenotypic information, which may improve tumour characterisation. In contrast to many other potential biomarkers, imaging can is non-invasive, and can assess multiple disease sites at multiple time-points across treatment; it may therefore have particular utility in the metastatic setting. Here, we discuss the existing and potential future roles for imaging as a biomarker in oligometastatic colorectal cancer, focusing on the capacity to assess a dynamic, heterogeneous disease.
11 November 2016, 11:00 (Friday, 5th week, Michaelmas 2016)
Old Road Campus Research Building, Headington OX3 7DQ
Room 71a, b & c
Dr Jamie Franklin
Department of Oncology
Dr Michael Youdell (University of Oxford),
Anne-Marie Honeyman-Tafa (University of Oxford)
Dr Claire Butler (University of Oxford)
CRUK & EPSRC Cancer Imaging Centre in Oxford
University staff, nhs staff and other interested parties